


Supplementary Materials

A



B









Figure S1. PKM2 deficiency reduces cell viability and induces apoptosis particularly in hypoxic condition. **(A)** Cell viability of H23 and H1299 cells transfected with siCon or siPKM2. Each cell was incubated in normoxia or 3% O₂ hypoxia for the indicated time. Cell numbers were determined by automated cell counter after staining with Trypan blue (n = 3). Statistical significance was measured using one-way ANOVA with the Tukey post hoc test. *P < 0.05, **P < 0.01. **(B)** The levels of PARP cleavage in A549 and H1299 cells transfected with siCon or siPKM2 under normoxic or hypoxic (1% O₂) conditions for 24h. β -Actin was used as a loading control.

A


Calu-3

**B****C**

A549

■ Normoxia ■ 3% O₂ (24h)**D****E****F**

Calu-3












G**H****I****J****K****L****M**

Figure S2. PKM2 deficiency reduces IGF-1R signaling-mediated cell survival by suppressing its expression in hypoxic conditions. **(A)** Phosphorylated AKT levels in Calu-3 cells transfected with siCon or siPKM2 under normoxic or hypoxic (1% O₂) conditions. **(B)** Phosphorylated AKT levels in H1299 and H23 cells transfected with siCon or siPKM2 under hypoxic (1% O₂) condition for 24h. Total AKT was used as a loading control. **(C)** The levels of mRNA expression of anti-apoptotic genes in A549 cells transfected with control siRNA or PKM2 siRNA under normoxic or hypoxic conditions (3% O₂) for 24 h, normalized to β -actin mRNA. Values of graph were presented as mean \pm SD. Statistical significance was measured using one-way ANOVA with the Tukey post hoc test. *P < 0.05, **P < 0.01. **(D)** Abundance of IGF-1R protein in A549, H1299 and H23 cells transfected with siCon or siPKM2 under hypoxic (1% O₂) condition for 24 h. **(E)** The levels of IGF-1R mRNA expression in A549, H1299 and H23 cells transfected with siCon or siPKM2 under hypoxic (1% O₂) condition for 24 h. **(F)** Another field of confocal microscopic images of endogenous IGF-1R and PKM2 detected by immunofluorescence in Calu-3 cells transfected with PKM2 siRNA under hypoxic condition (1% O₂) for 6h. **(G)** Cleaved PARP, IGF-1R and phosphorylated AKT protein abundance in Calu-3 cells transfected with control siRNA or IGF-1R siRNA under normoxia or hypoxia (1% O₂) for 24 h. β -Actin was used as a loading control. **(H)** Cell viability of Calu-3 cells transfected with IGF-1R siRNA under normoxia and hypoxia (1% O₂) for the indicated periods. Cell numbers were measured by automated cell counting after staining with Trypan blue (n = 3). Values are presented as mean \pm SD. Statistical significance was measured using the one-way ANOVA with the Tukey post-test. *P < 0.05 and **P < 0.01. **(I)** IGF-1R and p-AKT(S473) protein abundance in A549 cells transiently transfected with siPKM2 and/or Myc-tagged mouse PKM2 gene (Myc-mPKM2). **(J)** The effect of PKM2 restoration on IGF-1R protein expression in PKM2-depleted HeLa cells. IGF-1R and p-AKT(S473) protein abundance were determined in HeLa cells stably transfected with shPKM2 and transiently transfected with Myc-tagged mouse PKM2 gene (Myc-mPKM2) or mock vector. **(K)** Protein level of IGF-1R in A549 cells transiently transfected with different doses of Myc-tagged human PKM2 gene (Myc-hPKM2). **(L)** The effect of PKM1 overexpression on IGF-1R precursor or mature protein expressions. IGF-1R protein levels were determined in Calu-3 cells transiently transfected with different doses of Myc-tagged human PKM1 gene (Myc-hPKM1). **(M)** IGF-1R protein abundance in A549 cells transiently transfected with siPKM2 and/or Myc-tagged mutant mPKM2 genes. β -Actin was used as a loading control in **(A)**, **(D)**, **(E)**, **(G)** and **(I-M)**.


A  A549



B  Calu-3



C  Calu-3



D  A549





Figure S3. PKM2 physically binds to IGF-1R and regulates its stability via the ubiquitin-proteasome system. **(A)** IGF-1R and p-Ser473-AKT protein abundance in siPKM2-expressing A549 cells pre-treated with the proteasome inhibitors, MG132 (10 μ M) or Velcade (10 μ M). **(B)** Abundance of IGF-1R precursor and mature proteins in the anti-Flag immunoprecipitates from Calu-3 cells exogenously expressing IGF-1R and Flag-PKM2. **(C)** Endogeneous PKM2 protein abundance in anti-IGF-1R immunoprecipitates from Calu-3 cells under hypoxic condition (1% O₂) for 24h. Normal mouse IgG was used as the negative control. **(D)** Determination of precursor and mature IGF-1R protein stability in Flag-PKM2 expressing A549 cells following CHX (50 μ g/mL) treatment for the indicated time. β -Actin was used as the loading control in **(A-D)**.


A

Calu-3




B

A549



C



D




Figure S4. PKM2 regulates the IGF-1R/HSP90 interaction contributing to cancer cell viability. **(A)** Abundance of IGF-1R precursor and mature proteins present in Flag-HSP90 immunoprecipitates from Calu-3 cells transfected with control siRNA or PKM2 siRNA. Each cell was also exogenously transfected with IGF-1R and Flag-HSP90 cDNAs, as indicated. **(B)** Precursor and mature IGF-1R protein stability assessed following treatment with CHX (50 ug/ml) for the indicated time in A549 cells expressing Flag-HSP90 and/or siPKM2. **(C)** IGF-1R protein levels were determined in H23 and H1299 cells transiently transfected with Myc-tagged mouse PKM2 gene (Myc-mPKM2) and subsequently treated with the HSP90 inhibitor NVP-AUY922 (500 nM) for 24 h. **(D)** The effect of NVP-AUY922 (500 nM) treatment on the cell viability was determined in Myc-mPKM2 expressing Calu-3 and A549 cells, cultured under normoxic conditions or 3% O₂ for 24 h. The images were obtained using Olympus microscope IX71 with phase contrast. β -Actin was used as a loading control in **(A-C)**.




Figure S5. Whole membrane immunohistochemical images for PKM2 and IGF-1R expression in 112 human lung adenocarcinoma tissues.

Table S1. List of antibodies used in the study.

Target protein	Provider	Dilution factor
PKM2	Abnova (M01A)	WB(1:2000), ICC, IHC(1:200)
PKM2	Cell signaling (4053)	WB(1:2000)
IGF-1R	Abcam (ab182408)	ICC, IHC (1:200)
IGF-1R	Cell signaling (9750)	WB(1:1000)
Caspase-9	Cell signaling (9502)	WB(1:1000)
PARP	Cell signaling (9542)	WB(1:1000)
HIF-1a	BD bioscience (610958)	WB(1:1000)
β-Actin	Santa Cruz (sc-47778)	WB(1:2000)
p-AKT(ser308)	Cell signaling (4056)	WB(1:500)
p-AKT(ser473)	Cell signaling (4060)	WB(1:2000)
AKT	Cell signaling (9272)	WB(1:1000)
Myc-tag	Cell signaling (2278)	WB(1:1000)
HA-tag	Cell signaling (3724)	WB(1:1000)
Flag-tag	Sigma (F3165)	WB(1:5000)
K48-ubiquitin	Cell signaling(8081)	WB(1:1000)

Table S2. List of primer sequence used in RT-PCR analysis.

Target gene	Sequence
<i>Pkm2</i>	Forward : 5'-CCGCCGCCTGGCGCCCATTA-3' Reverse: 5'-CGGTCAGCACAATGACCACATC-3'
<i>Igf1r</i>	Forward : 5'- TGAGGATCAGCGAGAATGTG-3' Reverse: 5'-CAGAGGCATACAGCACTCCA-3'
<i>β-Actin</i>	Forward : 5'-CTGGAGAAGAGCTACGAGCTGC-3' Reverse : 5'-CTAGAAGCATTTCGCGGTGGACG-3'
<i>Bcl2</i>	Forward : 5'-GATGTGATGCCTCTGCGAAG-3' Reverse : 5'-CATGCTGATGTCTCTGGAATCT-3'
<i>Bcl2l1</i>	Forward : 5'-GAGCTGGTGGTTGACTTTCTC-3' Reverse : 5'-TCCATCTCCGATTCAGTCCCT-3'
<i>Mcl1</i>	Forward : 5'-AGAAAGCTGCATCGAACCAT-3' Reverse : 5'-CCAGCTCCTACTCCAGCAAC-3'